Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Department of Veterans Affairs (VA)
Pharma
Madrigal builds launch infrastructure for MASH drug Rezdiffra
Despite a reimbursement hurdle from the VA, Madrigal is still targeting 80% commercial coverage for its MASH drug Rezdiffra by year-end.
Angus Liu
May 7, 2024 11:56am
Biogen may lack shield against sluggish Aduhelm launch: analyst
Sep 22, 2021 10:01am
The VA decided not to cover Biogen's new Azlheimer's drug
Aug 11, 2021 11:30am
Merck wins national VA contract for its Remicade biosimilar
Oct 8, 2018 11:12am
Hospitals, sick of drug shortages, take issue into their own hands
Jan 18, 2018 12:02pm
